Regulatory affairs support. CCS associates, INC. N01DA-23-8933. September 20, 2023 to september 19, 2028.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95023D00025
- Awardee
-
CCS Associates, Inc. UEI VCNRS52G5PG7
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 4 $1,151,263 obligated
Award facts
- Opportunity
-
- Small Business Sources Sought: Phase I Clinical Trials for Development of Neurotherapeutics Pre-Solicitation · 75N95023R00009 · Posted Nov 18, 2022
- Combined order value
- $1,151,263 Current and potential, with all options
- Last date to order 62% complete
- IDV ceiling 48% used
- $2,400,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R699 Support- Administrative: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute on Drug Abuse awarded an indefinite-delivery contract to CCS Associates, Inc., a woman-owned small business, with a ceiling of $2.4 million on September 20, 2023. This is a single-award IDIQ.
Performance runs from September 20, 2023 through September 19, 2028. The contract supports regulatory affairs across NIDA drug development programs, encompassing regulatory document preparation, IND application support, Pre-IND application filing, and clinical trial regulatory preparation. Work is performed in San Jose, California.
The originating solicitation, posted as a pre-solicitation on November 18, 2022 and due December 2, 2022, carried a Total Small Business set-aside designation.
CCS Associates holds woman-owned small business status. The company self-performs all labor on federal services contracts and operates primarily as a prime contractor rather than layering subcontractors.
Recent delivery orders issued under this IDIQ include a cost-plus-fixed-fee order valued at $209,529 (March 27, 2026 through March 26, 2027) for regulatory preparation, review, and submission services for clinical trials under the NIDA Drug Supply Program; a $394,539 order (April 1, 2025 through March 31, 2026) for the same scope; a $307,737 order (April 1, 2024 through March 31, 2025); and a $113,077 order (September 20, 2023 through September 19, 2024). All delivery orders are cost-plus-fixed-fee and carry no set-aside. Performance location for all orders is San Jose, California.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95023D00025?
75N95023D00025 was awarded to CCS Associates, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 20, 2023.
How much is contract 75N95023D00025 worth?
Orders under 75N95023D00025 have obligated $1,151,263. 75N95023D00025's own ceiling is $2,400,000.
How many orders have been placed under contract 75N95023D00025?
4 orders have been placed under 75N95023D00025, the latest on March 27, 2026.
Who can order from contract 75N95023D00025?
75N95023D00025 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95023D00025 competed?
The extent of competition for 75N95023D00025 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV